XCell-Center Commences Neuro-endoscopic Autologous Stem Cell Treatments in Germany
Dusseldorf, Germany (PRWEB) October 7, 2009
The XCell-Center proudly announces that it has commenced treating patients via neuro-endoscopic autologous stem cell implantation (NEASCI™) at its state-of-the-art treatment facility in Dusseldorf, Germany.
This innovative technique allows neurosurgeons to implant stem cells directly into the fluid spaces that surround a patient’s brain thus achieving more accurate targeting of stem cells than with other implantation methods such as intrathecal or intravenous injection. All XCell-Center patients are treated with their own bone marrow-derived stem cells.
The XCell-Center is optimistic that NEASCI, (pronounced “nee-see”) will prove to be a valuable enhancement to its repertoire of stem cell implantation techniques that already include intrathecal injection and surgery for neurological disorders and spinal cord injury, angiography for heart disease and diabetes, retrobulbar injection for various eye diseases and intravenous/intramuscular injections for other indications.
NEASCI is especially suited to the treatment of neurological disorders such as cerebral palsy, organic brain damage, oxygen deficiency, congenital brain malformations and brain damage caused by inflammation from meningitis, encephalitis, cerebral hemorrhage or skull-brain trauma.
“As the world leader in autologous stem cell therapy, we are constantly striving to improve the effectiveness of our treatments by developing advanced technology such as NEASCI,” commented Dr. Uta Tamaschke, the pediatric neurosurgeon at the XCell-Center who developed NEASCI.
NEASCI is accomplished by inserting a mini-endoscope through a small hole (6 mm) in the patient’s skull. Once inside the cerebral fluid space, the stem cells are released via a catheter that is guided through the endoscope. Prior to surgery, physical and functional damage will be assessed by computer tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET).
Pricing for NEASCI treatment begins at 17,800 Euros.
About the XCell-Center
The XCell-Center operates treatment centers in Cologne and Dusseldorf, Germany. It is the first privately-owned clinic in Europe to specialize in regenerative medicine using autologous bone marrow stem cell therapy and operates in accordance with German law and European guidelines. Its specialized medical team of German physicians includes specialists in: neurosurgery, orthopedics, cardiology, radiology, anesthesiology and pharmacology.
The XCell-Center also treats Diabetes and its complications (Erectile Dysfunction and Peripheral Artery Disease), Stroke, Cerebral Palsy, Spinal Cord Injuries, Orthopedic diseases, Heart Disease and degenerative diseases such as Multiple Sclerosis, Parkinson’s, Alzheimer’s and several eye diseases.
For more information on Stem Cell Therapy:
XCell-Center Website: http://www.xcell-center.com
at the Institute for Regenerative Medicine
Am Heerdter Krankenhaus 2
40549 Dusseldorf, Germamy
Phone: 1-866-680-8202 (USA Toll-Free) (+49) 0221-802-5095 (Germany)
Fax: 1-713-583-9322 (USA) (+49) 0221-2921-2550 (Germany)
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.